Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour with an overall poor prognosis. In October 2020, first line treatment with the PD-1 antagonist nivolumab and the CTLA-4 antagonist ipilimumab for unresectable disease was FDA approved—the first approved treatment regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Kefas, Joanna, Harwood, Catherine, Lewis, Myles J., Szlosarek, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821830/
https://www.ncbi.nlm.nih.gov/pubmed/35130961
http://dx.doi.org/10.1186/s41927-021-00238-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821830/
https://www.ncbi.nlm.nih.gov/pubmed/35130961
http://dx.doi.org/10.1186/s41927-021-00238-8

Ejemplares similares